ASTS dropped from a previous close of $36.89 to about $35.45, a decline of -3.9%, during regular market hours on Tuesday. The slide follows Monday evening's Q3 double-miss, with EPS of -$0.44 versus -$0.40 expected and revenue of $42.32M versus roughly $47.9M, prompting traders to fade the prior session's +14.1% rally.

CWST dropped -7.32% to $91.77 from a $99.02 prior close during Tuesday's regular session, extending a slide that began in after-hours trading Monday. The decline followed a Q3 earnings miss: adjusted EPS of $0.35 versus the $0.42 consensus and revenue of $559.2M versus $563.8M, with a swing to a -$7.0M net loss tied to a Granite State landfill impairment charge.

Klaviyo (KVYO) fell during regular-session trading, sliding from a previous close of $20.82 to $19.84, a decline of -4.71%. The drop followed a Nov. 9 SEC Form 144 showing pre-IPO backer Summit Partners planned to sell roughly 2.74 million Class A shares (~$57M, about 2.1% of the class) through Barclays, creating supply overhang.

AUGO fell to $82.41 from a prior close of $86.99, a drop of -5.26%, in early regular trading after sliding in the premarket. The decline tracked a ~1.6% fall in spot gold to roughly $4,074 an ounce after a hawkish Federal Reserve official signaled more aggressive policy could be needed if inflation keeps rising, pressuring high-beta gold miners.

LINE dropped -7.74% to $36.59 from its prior close of $39.66, with the decline unfolding during regular market hours on Tuesday. The move follows third-quarter results reported after Monday's close: revenue fell 1.2%, the net loss widened, AFFO per share slid 14.1%, and management lowered full-year adjusted EBITDA and AFFO guidance.

GE Vernova (GEV) dropped from a $829.34 previous close to $780.56, down -5.88%, during regular market hours. No verified news or fundamental catalyst found. The decline looks like profit-taking that gave back most of yesterday's +7.13% surge on a German wind-turbine order, consistent with a technical pullback after a one-day rally.

Rocket Lab USA (RKLB) reported record quarterly revenue of $267.8 million, up 73% year over year and ahead of consensus estimates of roughly $258 million. GAAP (Generally Accepted Accounting Principles) net loss widened to $79.7 million, with a loss of $0.12 per share that missed the consensus estimate of about $0.07.

Barnes Group is expected to report its third quarter 2026 results around November 9–10, 2026, before the market opens. Consensus estimates point to earnings per share (EPS, a measure of profit divided by outstanding shares) of roughly $0.79, with revenue expectations near $5.16 billion, based on available analyst data.

Both QUBT and RGTI are pre-profit quantum computing stocks that have declined sharply in 2026 despite sector-wide rallies in recent weeks. QUBT has pivoted toward near-term commercialization through photonics acquisitions, while RGTI remains more dependent on lumpy, single-system hardware sales.

The MTNB central target of $2.50 is not an analyst consensus; it reflects a fallback objective tied to the stock's recent post-reverse-split trading level of roughly $2.48, since no credible current analyst price target exists. With shares near $1.24, reaching $2.50 would require a gain of roughly 102%, a very large move for a micro-cap valued near $1.2 million.

The $3.30 target is not an analyst consensus. It reflects the $14.5 million equity valuation assigned to Skye in its definitive merger agreement with Redx Pharma, spread across roughly 4.43 million post-split shares. With the stock trading near $0.80 after a 1-for-8 reverse split, reaching $3.30 implies upside of more than 300% — a very large move by any standard.

The $0.10 level examined here is a fallback reference point, not an analyst price target; every analyst price target set before the Chapter 11 filing is now obsolete. Karyopharm's stock has collapsed from roughly $0.66 before the filing to about $0.04, giving the company a market capitalization of only around $1 million to $2.5 million.

The central $29 target is the arithmetic mean of two verified analyst price targets: H.C. Wainwright at $13 and Noble Financial at $45. At a latest verified price near $1.37, reaching $29 would require upside of roughly 2,000% — a very large move by any standard.

The central target used here is $4 per share , a round-number, psychological level that sits just below short-term technical resistance near $4.12–$4.15. This objective comes from public discussion and technical analysis , not from an analyst consensus, because FCUV has no verifiable Wall Street price targets to aggregate.

The central target of $1.60 is not an analyst consensus; it reflects publicly discussed statistical-model commentary that places MPU in a roughly $1.10–$1.80 trading range with a mean forecast near $1.60. At a recent price near $1.21, reaching $1.60 would require an upside move of approximately 32%, a substantial recovery for a micro-cap stock.

Skye Bioscience (SKYE) is expected to report third quarter 2026 results after the market close around November 9–10, 2026. As a clinical-stage biotechnology company, Skye generates essentially no revenue, so investors will focus on operating expenses, net loss, and cash position rather than top-line growth.

The central target of $4 used here comes from publicly discussed quantitative and algorithmic forecasts, not from a Wall Street analyst consensus. GD Culture Group Limited (GDC) has no credible analyst price targets; the only tracked rating is a quantitative "Sell" from Weiss Ratings, with no price target attached.

Cadrenal Therapeutics is expected to report third-quarter 2026 results for the period ended September 30, 2026, with consensus estimates pointing to a net loss of $0.91 per share. Analysts expect a narrower loss compared with the $1.31 per-share loss reported in the same quarter a year earlier, reflecting a continuing trend of declining quarterly losses.

Peraso Inc. (PRSO) is expected to report its third-quarter 2026 results in mid-November, following its fiscal Q2 2026 report on August 11, 2026. Wall Street consensus models a non-GAAP loss of roughly $0.16 to $0.18 per share on revenue of approximately $1.1 million, implying a year-over-year revenue decline of about 66%.

The $3.10 central target is the arithmetic mean of the verified analyst price targets reviewed ($3.00 and $3.25), rounded from roughly $3.13. At the latest verified price near $0.35, reaching $3.10 would require upside of roughly 780%—a very large move for any security.